NasdaqCM:AVEO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has AVEO Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AVEO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.9%

AVEO

6.7%

US Biotechs

0.08%

US Market


1 Year Return

-36.9%

AVEO

31.2%

US Biotechs

12.8%

US Market

Return vs Industry: AVEO underperformed the US Biotechs industry which returned 31.2% over the past year.

Return vs Market: AVEO underperformed the US Market which returned 12.8% over the past year.


Shareholder returns

AVEOIndustryMarket
7 Day5.9%6.7%0.08%
30 Day29.7%1.7%-1.8%
90 Day9.6%-1.4%7.2%
1 Year-36.9%-36.9%33.4%31.2%15.3%12.8%
3 Year-82.4%-82.4%17.9%12.2%39.2%29.9%
5 Year-48.8%-48.8%19.6%11.3%88.3%67.1%

Price Volatility Vs. Market

How volatile is AVEO Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AVEO Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.36x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AVEO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AVEO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AVEO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AVEO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVEO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVEO is good value based on its PB Ratio (3.4x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is AVEO Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

48.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVEO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVEO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVEO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AVEO's revenue (52% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: AVEO's revenue (52% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AVEO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AVEO Pharmaceuticals performed over the past 5 years?

29.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVEO is currently unprofitable.

Growing Profit Margin: AVEO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVEO is unprofitable, but has reduced losses over the past 5 years at a rate of 29.8% per year.

Accelerating Growth: Unable to compare AVEO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVEO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: AVEO has a negative Return on Equity (-7.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is AVEO Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AVEO's short term assets ($74.2M) exceed its short term liabilities ($21.8M).

Long Term Liabilities: AVEO's short term assets ($74.2M) exceed its long term liabilities ($5.8M).


Debt to Equity History and Analysis

Debt Level: AVEO's debt to equity ratio (23.2%) is considered satisfactory.

Reducing Debt: AVEO's debt to equity ratio has reduced from 132.4% to 23.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVEO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AVEO has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 30.3% each year


Next Steps

Dividend

What is AVEO Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVEO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVEO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Michael Bailey (55 yo)

5.25yrs

Tenure

US$1,589,644

Compensation

Mr. Michael P. Bailey has been Chief Executive Officer and President of AVEO Pharmaceuticals, Inc. ( AVEO Oncology) since January 6, 2015 and served as its Secretary. He has been an Independent Director of ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD1.59M) is about average for companies of similar size in the US market ($USD1.28M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Bailey
CEO, President & Director5.25yrsUS$1.59m0.12%
$ 199.3k
Karuna Rubin
Senior VP & General Counsel5.17yrsUS$749.48k0%
$ 0
Michael Needle
Chief Medical Officer5.67yrsUS$720.18k0.020%
$ 32.4k
Erick Lucera
Chief Financial Officer0.67yrno datano data
Lisa Bruneau
VP of Financial Accounting & Reporting and Treasurer4.67yrsno datano data
Emile Farhan
Senior Vice President of Technical Operations & Quality Assuranceno datano datano data
Kevin Peacock
Vice President of Marketing0.83yrno datano data
Mike Ferraresso
Senior Vice President of Business Analytics & Commercial Operationsno datano datano data
Darlene Noci
Interim Head of Regulatory Affairs0.92yrno datano data

4.7yrs

Average Tenure

53yo

Average Age

Experienced Management: AVEO's management team is considered experienced (4.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Bailey
CEO, President & Director5.25yrsUS$1.59m0.12%
$ 199.3k
Anthony Evnin
Independent Director18.5yrsUS$83.36k0.16%
$ 261.5k
Kenneth Bate
Lead Independent Outside Directorno dataUS$103.36k0.0014%
$ 2.3k
Raju Kucherlapati
Member of Scientific Advisory Boardno dataUS$3.00kno data
Robert Young
Independent Director11.17yrsUS$76.86k0.0073%
$ 11.9k
Charles Sawyers
Member of Scientific Advisory Boardno datano datano data
H. Horvitz
Member of Scientific Advisory Boardno datano datano data
Tyler Jacks
Member of Scientific Advisory Boardno datano datano data
Lynda Chin
Member of Scientific Advisory Boardno datano datano data
Lewis Cantley
Member of Scientific Advisory Boardno datano datano data
Gregory Mayes
Independent Director1.58yrsUS$93.40k0%
$ 0
Douglas Hanahan
Member of Scientific Advisory Boardno datano datano data

8.2yrs

Average Tenure

70yo

Average Age

Experienced Board: AVEO's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 60.6%.


Top Shareholders

Company Information

AVEO Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AVEO Pharmaceuticals, Inc.
  • Ticker: AVEO
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$161.302m
  • Shares outstanding: 25.81m
  • Website: https://www.aveooncology.com

Number of Employees


Location

  • AVEO Pharmaceuticals, Inc.
  • 30 Winter Street
  • Boston
  • Massachusetts
  • 2108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AVEONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 2010
VPA1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2010

Biography

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, ti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/21 05:53
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.